Metraipolis › archive › dc_2ccd585cee71

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing — Europe PMC PMID:42497217

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42497217
DOI: 10.1371/journal.pone.0352967
License (as archived): solo-consultazione
Archived: 2026-10-06T17:29:04.009Z
SHA-256 of the archived text: d5e9d04dba4ac919958011daa66c19350f9ba8ab5b8497992e3348311109e521
Stable URL of this page: https://metraipolis.com/documento/dc_2ccd585cee71

How to cite

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing — Europe PMC PMID:42497217 — Europe PMC (en), https://europepmc.org/article/MED/42497217 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2ccd585cee71 (Metraipolis archive dc_2ccd585cee71, sha256 d5e9d04dba4ac919958011daa66c19350f9ba8ab5b8497992e3348311109e521)

BibTeX

@misc{dc2ccd585cee71,
  title = {Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing — Europe PMC PMID:42497217},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42497217},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2ccd585cee71; sha256 d5e9d04dba4ac919958011daa66c19350f9ba8ab5b8497992e3348311109e521},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42497217. Agents can read the archived copy with the MCP tool read_document.